Open Access<p>miR-34c Targets MET to Improve the Anti-Tumor Effect of Cisplatin on Ovarian Cancer</p>
Author(s) -
Shiying Yang,
Zhen Li,
Rui Luo
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s239425
Subject(s) - cisplatin , ovarian cancer , cancer research , pi3k/akt/mtor pathway , protein kinase b , cytotoxicity , apoptosis , flow cytometry , mtt assay , downregulation and upregulation , cancer , in vivo , medicine , chemistry , in vitro , oncology , immunology , biology , chemotherapy , gene , biochemistry , microbiology and biotechnology
Cisplatin is a commonly used drug for the treatment of various types of malignant cancers, including ovarian cancer. However, resistance to cisplatin is still a considerable obstacle to achieve a satisfactory therapeutic effect. The purpose of this study is to develop a strategy to sensitize ovarian cancer cells to cisplatin-induced cytotoxicity.